PRLD Share Price Performance
US$4.52
3.36 (289.66%)
54.8% undervalued intrinsic discount
US$10.00
Fair Value
Price US$4.52
AnalystHighTarget US$10.00
AnalystLowTarget US$3.00
Fair ValueUS$10.00
Share Pricen/a
Seeking Alpha • Aug 23
Prelude Therapeutics Incorporated Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
PRLD Community Narratives
AN
Fair Value
·Fair Value US$10 54.8% undervalued intrinsic discount
Future Oncology Platform Will Be Transformed By Targeted Degraders And JAK2-Focused Precision Therapies
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$3 50.7% overvalued intrinsic discount
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Prelude Therapeutics
54.8% undervalued intrinsic discount
Future Oncology Platform Will Be Transformed By Targeted Degraders And JAK2-Focused Precision Therapies
View narrativeAN
Updated 26 Jun
Prelude Therapeutics
50.7% overvalued intrinsic discount
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
View narrativeAN
Published 6 Mar
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
PRLD: Metastatic Breast Cancer Program Will Drive Upside From Early-Stage Platform
Fair Value: US$10 54.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
Fair Value: US$3 50.7% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Prelude Therapeutics Incorporated Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.59
- 100.00%
- -269.75%
- 0%
About PRLD
- Founded
- 2016
- Employees
- 79
- CEO
- WebsiteView website
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
